| T-cell exhaustion induced by continuous bispecific molecule exposure is ameliorated by treatment-free intervals N Philipp, M Kazerani, A Nicholls, B Vick, J Wulf, T Straub, M Scheurer, ... Blood, The Journal of the American Society of Hematology 140 (10), 1104-1118, 2022 | 82 | 2022 |
| STING agonism turns human T cells into interferon‐producing cells but impedes their functionality N Kuhl, A Linder, N Philipp, D Nixdorf, H Fischer, S Veth, G Kuut, TT Xu, ... EMBO reports 24 (3), e55536, 2023 | 22 | 2023 |
| Protective immune trajectories in early viral containment of non-pneumonic SARS-CoV-2 infection K Pekayvaz, A Leunig, R Kaiser, M Joppich, S Brambs, A Janjic, O Popp, ... Nature communications 13 (1), 1-21, 2022 | 22 | 2022 |
| Adapter CAR T cells to counteract T-cell exhaustion and enable flexible targeting in AML D Nixdorf, M Sponheimer, D Berghammer, F Engert, U Bader, N Philipp, ... Leukemia, 1-13, 2023 | 13 | 2023 |
| P04. 01 Immunomonitoring of CD19. CAR T-cells in Large B-Cell Lymphoma-a two-center experience V Blumenberg, S Völkl, G Busch, S Baumann, M Winkelmann, B Tast, ... Journal for ImmunoTherapy of Cancer 9 (Suppl 1), 2021 | 2 | 2021 |
| TET1 drives global DNA demethylation via DPPA3-mediated inhibition of maintenance methylation CB Mulholland, J Ryan, W Qin, MD Bartoschek, FR Traube, E Parsa, ... bioRxiv, 321604, 2018 | 2 | 2018 |
| CD33-TIM3 Dual CAR T Cells: Enhancing Specificity While Maintaining Efficacy Against AML Y Wang, W Lu, L Rohrbacher, H Flaswinkel, AJ Emhardt, G Magno, ... Blood 142, 3449, 2023 | 1 | 2023 |
| Two Players, One Goal: BiTE® Vs CART Targeting FLT3 in AML L Rohrbacher, D Nixdorf, H Stadler, B Brauchle, F Märkl, N Philipp, ... Blood 142, 3444, 2023 | 1 | 2023 |
| Treatment-Free Intervals during CD19xCD3 BiTE® Construct-Mediated T-Cell Stimulation Induce Functional Reinvigoration and Transcriptional Reprogramming of Exhausted T Cells N Zieger, MK Pasikhani, T Straub, A Nicholls, G Hänel, J Wulf, M Scheurer, ... Blood 138, 513, 2021 | 1 | 2021 |
| Treatment-Free Intervals Mitigate T-Cell Exhaustion Induced By Continuous CD19xCD3-BiTE® Construct Stimulation in Vitro N Zieger, A Nicholls, J Wulf, G Hänel, MK Pasikhani, V Buecklein, ... Blood 136, 44-45, 2020 | 1 | 2020 |
| Combining venetoclax and azacytidine with T-cell bispecific antibodies for treatment of acute myeloid leukemia: a preclinical assessment G Hänel, A Schönle, AS Neumann, D Nixdorf, N Philipp, M Sponheimer, ... Leukemia, 1-5, 2024 | | 2024 |
| Single-Cell Transcriptomic Profiling of T Cells from Blinatumomab-Treated Patients with B-Cell Precursor Acute Lymphoblastic Leukemia (BCP-ALL) Reveals Circulating CD8 T Cell … F Corrado, J Wulf, T Straub, D Nixdorf, A Marcinek, N Philipp, CF Chu, ... Blood 142, 600, 2023 | | 2023 |
| Rational Combinatorial Targeting By Adapter CAR T Cells (AdCAR-T) Prevents Antigen Escape in Acute Myeloid Leukemia (AML) D Atar, L Ruoff, AS Mast, S Krost, M Moustafa-Oglou, S Scheuermann, ... Blood 142, 6834, 2023 | | 2023 |
| Beyond Mitigating Immune-Related Adverse Events: Glucocorticoids Ameliorate Bispecific Antibody-Mediated T-Cell Exhaustion I n Vitro A Muth, N Philipp, A Marcinek, T Straub, L Winter, G Hänel, D Nixdorf, ... Blood 142, 5389, 2023 | | 2023 |
| Sting Activation Improves T-Cell Engaging Immunotherapy of Acute Myeloid Leukemia A Linder, D Nixdorf, N Kuhl, I Piseddu, TT Xu, G Kuut, S Veth, T Carell, ... Blood 142, 2055, 2023 | | 2023 |
| Accomplices in Cure: Blinatumomab+ Dasatinib Reduces TCR Signaling and Effector Function Stronger Than Ponatinib and Ameliorates T-Cell Exhaustion N Philipp, A Marcinek, G Hänel, D Nixdorf, VL Buecklein, M Subklewe Blood 142, 1511, 2023 | | 2023 |
| The race is on: BiTE vs CART targeting FLT3 in AML L Rohrbacher, D Nixdorf, H Stadler, B Brauchle, F Märkl, N Philipp, ... Cancer Research 83 (7_Supplement), 894-894, 2023 | | 2023 |
| The Race Is on: BiTE Vs CART As FLT3-Directed Immunotherapies in AML L Rohrbacher, D Nixdorf, H Stadler, B Brauchle, F Märkl, N Phillip, ... Blood 140 (Supplement 1), 10233-10234, 2022 | | 2022 |
| Uncovering the Enemy: Single-Cell Transcriptional Profiling of Measurable Residual Disease (MRD) Cells M Kazerani, L Wange, B Tast, M Solovey, D Nixdorf, L Rohrbacher, ... Blood 140 (Supplement 1), 6321-6322, 2022 | | 2022 |
| 266 STING activation improves T cell engaging immunotherapy of acute myeloid leukemia D Nixdorf, A Linder, N Kuhl, TT Xu, R Kischel, V Bücklein, T Carell, ... Journal for ImmunoTherapy of Cancer 10 (Suppl 2), 2022 | | 2022 |
